Autopsy report · NCT03666728

A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

“changes in the R\&D strategy”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year 3 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Sponsor type

Industry

Conditions

Lung Neoplasms

Interventions

SHR-1210; BP102

Participants

5

Sites

1

Countries

China

Trials that died the same way

• Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
  “R\&D strategy adjustment” (86% match in meaning)
• A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
  “Sponsor R \& D Strategy Adjustment” (69% match in meaning)
• A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
  “The sponsor's R\&D strategy is adjusted.” (67% match in meaning)
• A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
  “Sponsor's R\&D strategy adjusted.” (67% match in meaning)
• Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL
  “The sponsor has adjusted its R\&D strategy.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.